¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"congenital immunologic thrombocytopenia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • congenital
    ¼±Ãµ-
  • congenital adrenal hyperplasia
    ¼±ÃµºÎ½Å°ú´ÙÇü¼º, ¼±ÃµÄáÆÏÀ§»ù°ú´ÙÇü¼º
  • congenital amputation
    ¼±Ãµ¼ºÀý´Ü
  • congenital aural fistula
    ¼±Ãµ±Ó¹ÙÄû¾Õ»û±æ, ¼±ÃµÀÌÀüºÎ´©°ø
  • congenital bullous icthyosiform erythroderma
    ¼±Ãµ¹°Áýºñ´ÃÁõ¸ð¾çÈ«»öÇǺÎ(Áõ), ¼±Ãµ¼öÆ÷ºñ´ÃÁõ¸ð¾çÈ«»öÇǺÎ(Áõ)
  • congenital cataract
    ¼±Ãµ¹é³»Àå
  • congenital constriction band
    ¼±ÃµÇùÂø¶ì
  • congenital contractural arachnodactyly
    ¼±Ãµ±¸Ãà°Å¹Ì°¡¶ôÁõ
  • congenital defect
    ¼±Ãµ°áÇÔ, ¼±Ãµ°á¼Õ(Áõ)
  • congenital dislocation of the hip
    ¼±Ãµ°í°üÀýÅ»±¸, ¼±Ãµ¾ûµ¢°üÀýÅ»±¸
  • congenital generalized fibromatosis
    ¼±ÃµÀü½Å¼¶À¯Á¾Áõ
  • congenital giant pigmented nevus
    ¼±Ãµ°Å´ë»ö¼Ò¸ð¹Ý
  • congenital glaucoma
    ¼±Ãµ³ì³»Àå
  • congenital hairy nevus
    ¼±ÃµÅиð¹Ý
  • congenital heart disease
    ¼±Ãµ½ÉÀ庴
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic deficiency state
    ¸é¿ª°áÇÌ»óÅÂ
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªºÒÀÀ»óÅÂ
  • acyanotic congenital cardiopathy
    ºñû»ö¼±Ãµ½ÉÀ庴Áõ
  • congenital contractural arachnodactyly
    ¼±Ãµ±¸Ãà°Å¹Ì°¡¶ôÁõ
  • congenital oculomotor apraxia
    ¼±ÃµÈ´º¸±â¸øÇÔÁõ
  • congenital
    ¼±Ãµ-
  • congenital cataract
    ¼±Ãµ¹é³»Àå
  • congenital defect
    ¼±Ãµ°áÇÔ, ¼±Ãµ°á¼Õ(Áõ)
  • congenital megacolon
    ¼±ÃµÅ«°áÀåÁõ
  • congenital syphilis
    ¼±Ãµ¸Åµ¶
  • congenital torticollis
    ¼±Ãµ±â¿î¸ñ
  • congenital alveolar dysplasia
    ¼±ÃµÆóÆ÷Çü¼ºÀÌ»ó, ¼±ÃµÇãÆÄ²Ê¸®Çü¼ºÀÌ»ó
  • congenital aural fistula
    (¢¡congenital preauricular fistula) ¼±Ãµ±Ó¹ÙÄû¾Õ»û±æ, ¼±ÃµÀÌÀüºÎ´©°ø
  • congenital bullous icthyosiform erythroderma
    ¼±Ãµ¹°Áýºñ´ÃÇǺÎÁõ¸ð¾çÈ«»öÇǺÎÁõ
  • congenital constriction ring syndrome
    ¼±ÃµÇùÂø°í¸®ÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infantile spasmodic paraplegia =congenital spas tic p.
    ¼±Ãµ¼º °æ·Ã¼º ¾çÇÏÁö¸¶ºñ, ¼±Ãµ¼º °æ·Ã¼º ÇϹݽŸ¶ºñ(à»ô¸àõÌâÕý àõù»ÚâãóØ«Ýö).
  • infantile spasmodic paraplegia =congenital spas tic p.
    ¼±Ãµ¼º °æ·Ã¼º ¾çÇÏÁö¸¶ºñ, ¼±Ãµ¼º °æ·Ã¼º ÇϹݽŸ¶ºñ(à»ô¸àõÌâÕý àõù»ÚâãóØ«Ýö).
  • pulverulent congenital cataract
    °¡·ç¸ð¾ç¼±Ãµ¹é³»Àå, ºÐ¸»»ó¼±Ãµ¹é³»Àå
  • reduplicated congenital cataract
    Áߺ¹¼±Ãµ¹é³»Àå
  • immunologic
    ¸é¿ªÀÇ
  • immunologic deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • immunologic deficiency syndrome
    ¸é¿ª°áÇÌ ÁõÈıº(¡­ÌÀù¹ ñøý¦ÏØ)
  • immunologic electron microscopy
    ¸é¿ªÀüÀÚÇö¹Ì°æ¹ý.
  • immunologic engineering
    ¸é¿ª°øÇÐ.
  • immunologic function
    ¸é¿ª±â´É.
  • immunologic infertilily
    ¸é¿ªÇÐÀûºÒÀÓ
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • immunologic intervention
    ¸é¿ª(ÇÐÀû)Á¶Á¤.
  • immunologic memory
    ¸é¿ª±â¾ï.
  • immunologic reaction
    ¸é¿ª¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • thrombocytopenia purpura hemorrhagica ³ª
    ÃâÇ÷¼º Ç÷¼ÒÆÇ°¨¼Ò¼º ÀÚ¹ÝÁõ(õóúìàõúìá³÷ùÊõá´àõí¹Úèñø)
  • autoimmune disease,immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • immunologic
    ¸é¿ªÀÇ
  • immunologic deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • immunologic deficiency syndrome
    ¸é¿ª°áÇÌ ÁõÈıº(¡­ÌÀù¹ ñøý¦ÏØ)
  • immunologic electron microscopy
    ¸é¿ªÀüÀÚÇö¹Ì°æ¹ý.
  • immunologic engineering
    ¸é¿ª°øÇÐ.
  • immunologic function
    ¸é¿ª±â´É.
  • immunologic infertilily
    ¸é¿ªÇÐÀûºÒÀÓ
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • immunologic intervention
    ¸é¿ª(ÇÐÀû)Á¶Á¤.
  • immunologic memory
    ¸é¿ª±â¾ï.
  • immunologic reaction
    ¸é¿ª¹ÝÀÀ
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CAV congenital absence of vagina; congenital adrenal virilism; constant angular velocity; croup-associat...
CC calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card...
CHA Canadian Hospital Association; Catholic Health Association; Chinese hamster; chronic hemolytic anemi...
CHD Chediak-Higashi disease; childhood disease; chronic hemodialysis; congenital or congestive heart dis...
TAR Thrombocytopenia-Absent Radius
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NAIT Neonatal alloimmune thrombocytopenia
NAITP Neonatal alloimmune thrombocytopenia
TP Thrombocytopenia
TAR Thrombocytopenia absent radius
TAR Thrombocytopenia with Absent Radii
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bullous congenital icthyosiform erythroderma
    ¼öÆ÷¼º ¼±Ãµ¼º ¾î¸°¼±»ó È«ÇÇÁõ
  • congenital abducens-facial paralysis
    ¼±Ãµ¼º ¿ÜÀü ¾È¸é ½Å°æ¸¶ºñ
    µ¿ÀǾî=Mobius syndrome.
  • congenital absence
    ¼±Ãµ¼º °á¿©, ¼±Ãµ¼º °á¿©Áõ
  • congenital allergy
    ¼±Ãµ¼º ¾Ë·¹¸£±â
  • congenital alveolar dysplasia
    ¼±Ãµ¼º ÆóÆ÷ ÀÌÇü¼º, ¼±Ãµ¼º ÆóÆ÷ ÀÌÇü¼ºÁõ
  • congenital amputation
    ¼±Ãµ¼º Àý´Ü, ÀÚ¿¬ Àý´Ü
    µ¿ÀǾî=natural am
  • congenital and developmental bone disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º °ñ Àå¾Ö
  • congenital and developmental muscle disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º ±ÙÀå¾Ö
    Ãâ»ý ½ÃºÎÅÍ ±ÙÀúÇϸ¦ ³ªÅ¸³»°í Èå´ÃÈå´ÃÇÑ ¾ÆÀÌ. flo
  • congenital aneurysm
    ¼±Ãµ¼º µ¿¸Æ·ù
  • congenital anomaly
    ¼±Ãµ ÀÌ»ó, ¼±Ãµ¼º ÀÌ»ó
  • congenital aplasia
    ¼±Ãµ¼º ¹«Çü¼º, ¼±Ãµ¼º ¹«Çü¼ºÁõ
  • congenital bullous ichthyosiform erythroderma
    ¼±Ãµ¼º ¼öÆ÷¼º ¾î¸°¼±¾ç È«ÇÇÁõ
  • congenital cause
    ¼±ÃµÀû ¿øÀÎ
  • congenital cholesteatoma
    ¼±Ãµ ÁøÁÖÁ¾, ¼±Ãµ¼º ÁøÁÖÁ¾
  • congenital cyst
    ¼±Ãµ¼º ³¶
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
adjuvants, immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
(12 Dec 1998)
receptors, immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere.
(12 Dec 1998)
graft enhancement, immunologic The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
(12 Dec 1998)
monitoring, immunologic Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc.
(12 Dec 1998)
contraception, immunologic Contraceptive methods utilizing immunologic processes.
(12 Dec 1998)
cytotoxicity, immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
(12 Dec 1998)
cytotoxicity tests, immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement.
(12 Dec 1998)
suppressor factors, immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory.
(12 Dec 1998)
desensitization, immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
immunologic <immunology> Pertaining to immunology.
(18 Nov 1997)
immunologic and biological factors A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity.
(12 Dec 1998)
immunologic capping The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens.
(12 Dec 1998)
immunologic deficiency syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
(12 Dec 1998)
immunologic diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated or both.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á